Does BPC-157 Cause Cancer? What the Research Actually Shows

No published study has shown that BPC-157 causes cancer, and standard tests have not flagged it as genotoxic. The real, unresolved question is theoretical: because BPC-157 promotes blood-vessel growth (angiogenesis) in animal models, researchers debate whether it could feed a tumor that already exists. Human data are absent. Consult your healthcare provider.

BPC-157 and cancer at a glance

• Does it cause cancer? No study to date has demonstrated that BPC-157 initiates cancer or damages DNA.
• The actual concern: BPC-157 is pro-angiogenic — it upregulates VEGFR2 and grows new blood vessels in animal models. Tumors also need blood vessels.
• What the lab data show: Mixed. One in-vitro study found BPC-157 inhibited melanoma-cell growth; the angiogenic mechanism is a theoretical risk, not a demonstrated one.
• Human evidence: None. No long-term human safety or carcinogenicity studies exist.
• Evidence quality: Low. Most research comes from one core research group, almost entirely in rodents and cell cultures.
• FDA status (June 2026): Not approved; removed from the 503A Category 2 list in April 2026; under PCAC review July 23–24, 2026.

Does BPC-157 cause cancer, according to the research?

The short answer is that no published study has shown BPC-157 to cause cancer. BPC-157 (body protection compound-157) is a synthetic pentadecapeptide — a 15-amino-acid chain — derived from a protein found in human gastric juice. It is studied in animal models for tissue repair, and to date no genotoxicity or mutagenicity testing in the published record has flagged it as DNA-damaging, and no rodent study has reported that healthy animals given BPC-157 developed tumors at higher rates than controls.

That is an important distinction. "Causing cancer" (carcinogenesis) means initiating the genetic damage that turns a healthy cell malignant. There is no evidence BPC-157 does this. The concern that circulates in biohacking communities is a different and more nuanced one — it is about progression, not initiation — and it stems directly from how BPC-157 is thought to work.

This article separates what the research actually demonstrates from what remains theoretical. For a broader overview of the peptide itself, see our BPC-157 complete guide.

Why do people worry BPC-157 might cause cancer?

The worry traces back to one of BPC-157's headline mechanisms: angiogenesis, the growth of new blood vessels. The same property that makes a peptide attractive for healing wounds, tendons, and ligaments is the property that makes oncologists cautious, because solid tumors cannot grow beyond a few millimeters without recruiting their own blood supply.

In a frequently cited study, Hsieh and colleagues reported that BPC-157 promoted angiogenesis in a rat hind-limb ischemia model and in human endothelial cell cultures, and that this effect was associated with increased expression and internalization of VEGFR2 (vascular endothelial growth factor receptor 2) and activation of the VEGFR2–Akt–eNOS signaling pathway (Hsieh et al., 2017, J Mol Med). VEGFR2 signaling is one of the central pathways tumors hijack to build their blood supply, which is why this mechanism gets flagged.

A 2025 commentary went further, arguing that BPC-157's pro-angiogenic and nitric-oxide-stimulating actions mean oncologic risk has not been adequately ruled out by the existing tumor-free animal data (Józwiak et al., 2025, Pharmaceuticals, a reply commentary on angiogenesis and nitric-oxide actions). In other words, the strongest published critique is not "BPC-157 causes cancer" but "the studies needed to confirm it is safe in the context of cancer have not been done."

What does the lab evidence actually show about BPC-157 and tumors?

The direct evidence is sparse and, notably, points in the opposite direction from the theoretical fear. In an in-vitro study using a human melanoma cell line, Radeljak and colleagues reported that BPC-157 inhibited melanoma-cell growth — lowering the S-phase (active cell-division) fraction by up to roughly 55% — and that it appeared to act as an antimitogenic agent by preventing ERK phosphorylation in the MAPK signaling cascade triggered by VEGF (Radeljak et al., 2004, Melanoma Research). That is a single, unreplicated cell-culture study, so it is far from definitive, but it is the most direct cancer-cell data available and it does not support the idea that BPC-157 accelerates this tumor type in a dish.

Separately, a 2018 paper proposed BPC-157 as a candidate for counteracting cancer cachexia — the muscle-wasting and inflammatory syndrome that affects late-stage cancer patients — reporting that in a tumor-bearing model it reduced muscle loss and procachectic cytokines such as IL-6 and TNF-α (Kang et al., 2018, Current Pharmaceutical Design). Importantly, that study addressed wasting symptoms and muscle biology, not tumor shrinkage, so it should not be read as evidence that BPC-157 treats or shrinks tumors.

The honest summary: no published in-vivo study demonstrates that BPC-157 grows, accelerates, or spreads tumors, and the one direct cancer-cell study found inhibition — but the database is too thin to call the question closed.

How strong is the evidence on BPC-157 safety overall?

Weak, and that is the most important safety caveat. BPC-157's healing mechanisms are reasonably characterized in animals — its pro-survival and pro-migration effects on tendon fibroblasts, for example, were mapped through the FAK-paxillin pathway in a foundational study (Chang et al., 2011, J Appl Physiol) — but the cancer-relevant safety picture rests on a narrow base.

Three limitations matter:

• Concentration of authorship. A large share of the BPC-157 literature comes from a single core research group, and independent replication is limited. This reduces confidence in any conclusion, positive or negative.
• Species gap. Nearly all data are in rodents or cell cultures. Effects, doses, and risks do not translate one-to-one to humans.
• No long-term human data. There are no published long-term human safety studies and no human carcinogenicity studies. Anyone claiming BPC-157 is "proven safe" — or "proven dangerous" — for cancer risk in humans is overstating the evidence in either direction.

Because pure educational sources cannot anticipate your personal cancer history or genetic risk, consult your healthcare provider before considering any peptide protocol. This is especially critical if you have a personal or family history of cancer, an active or prior malignancy, or undiagnosed lumps, lesions, or symptoms — the theoretical angiogenesis concern is most relevant when a tumor may already be present.

Should people with cancer or a cancer history avoid BPC-157?

This is where the theoretical concern carries the most practical weight, and it is a decision only a qualified clinician can make with you. The mechanistic logic is straightforward: a pro-angiogenic, VEGFR2-activating compound (Hsieh et al., 2017) is exactly the kind of agent that warrants extra caution in anyone with an active tumor, a recent cancer diagnosis, or an elevated genetic risk, because tumor angiogenesis is a recognized driver of cancer progression. The published animal data have not shown BPC-157 accelerating tumors, but the studies designed to rule that out in a cancer context have not been done.

Peptides.NYC does not sell peptides and cannot advise on individual risk. If you are in active treatment, in remission, or carry a known cancer predisposition, this is a conversation to have explicitly with your oncologist or healthcare provider before considering BPC-157. Consult your healthcare provider before starting any peptide protocol.

Is BPC-157 FDA-approved or legal? (June 2026)

BPC-157 is not FDA-approved for any use. Its regulatory status shifted significantly in 2026. In April 2026, the FDA removed BPC-157 — along with a group of other peptides — from the 503A Category 2 list, the category the agency had used to flag bulk substances that "may present significant safety risks" for pharmacy compounding (FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks).

Removal from Category 2 is not the same as approval. As of June 2026, BPC-157 has not been added to the 503A Category 1 bulks list, which means licensed pharmacies still cannot legally compound it through that pathway, and it defaults to an unapproved new drug. The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to review bulk drug substances, with BPC-157's compounding status among the matters under consideration (FDA, July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee). Products sold online as "research use only" are not quality-controlled for human use.

Legal status varies by jurisdiction; consult a lawyer for binding advice. For the current detailed picture, see our BPC-157 legal status guide.

Frequently asked questions

Q: Does BPC-157 cause cancer? A: No published study has shown that BPC-157 causes cancer, and standard genotoxicity testing in the literature has not flagged it as DNA-damaging. The concern discussed by researchers is theoretical and about progression rather than initiation: because BPC-157 promotes blood-vessel growth in animal models, some scientists question whether it could support a tumor that already exists. Human data are absent. Consult your healthcare provider, especially if you have any cancer history.

Q: Is BPC-157 carcinogenic or genotoxic? A: There is no published evidence that BPC-157 is carcinogenic (cancer-causing) or genotoxic (DNA-damaging). No rodent study has reported increased tumor rates in healthy animals given BPC-157. However, the overall safety database is small, dominated by one research group, and lacks any long-term human studies — so "no evidence of harm" is not the same as "proven safe."

Q: Why is BPC-157's effect on angiogenesis a concern for cancer? A: Tumors need new blood vessels to grow beyond a few millimeters. BPC-157 has been shown to promote angiogenesis and upregulate VEGFR2, a receptor tumors use to build their blood supply (Hsieh et al., 2017, J Mol Med). The theoretical worry is that this same vessel-building action could feed a pre-existing tumor — though no study has demonstrated this occurring.

Q: Has BPC-157 ever shown anti-cancer effects? A: In one in-vitro study, BPC-157 inhibited human melanoma-cell growth by interfering with VEGF-driven MAPK/ERK signaling (Radeljak et al., 2004, Melanoma Research). A separate study explored BPC-157 for reducing cancer-related muscle wasting (cachexia), not tumor size (Kang et al., 2018). These are isolated findings and do not establish BPC-157 as an anti-cancer agent.

Q: Should I take BPC-157 if I have a family history of cancer? A: This is a decision for your healthcare provider, not an article. Because BPC-157 is pro-angiogenic, the theoretical cancer-progression concern is most relevant for anyone with an active tumor, prior malignancy, or elevated genetic risk. Discuss your specific history with a qualified clinician before considering any peptide protocol.

Q: Is BPC-157 legal and FDA-approved in 2026? A: BPC-157 is not FDA-approved. It was removed from the 503A Category 2 compounding list in April 2026 but has not been approved for compounding, and currently defaults to an unapproved new drug. A PCAC review is scheduled for July 23–24, 2026. Legal status varies by jurisdiction; consult a lawyer for binding advice.

References

1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780. PMID: 21148156. DOI: 10.1152/japplphysiol.00945.2010.
2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017;95(3):323–333. PMID: 27847966. DOI: 10.1007/s00109-016-1488-y.
3. Radeljak S, Seiwerth S, Sikiric P. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14. Melanoma Research citation. [VERIFY: exact page/volume locator — abstract indexed in Melanoma Research 2004; full PMID not located]
4. Kang EA, Han YM, An JM, et al. BPC157 as Potential Agent Rescuing from Cancer Cachexia. Current Pharmaceutical Design. 2018;24(18):1947–1956. DOI: 10.2174/1381612824666180614082950. PMID: 29898649.
5. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Pharmaceuticals (Basel). 2025;18(10):1451. PMID: 41155566. DOI: 10.3390/ph18101451.
6. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA.gov. [VERIFY: April 2026 removal of BPC-157 from Category 2 — reported by multiple regulatory trackers; confirm against the dated FDA list revision.]
7. U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov advisory committee calendar.